No Data
No Data
Changes in Hong Kong stocks | Columbotai Biotech (06990) has now fallen by more than 4%, net allotment of shares raised more than HK$1.2 billion, of which nearly 700 million were subscribed by controlling shareholders
Columbotai Bio-B (06990) is now down more than 4%. As of press release, it is down 3.35% to HK$155.6, with a turnover of HK$108 million.
Columbotai Bio-B (06990.HK) plans to place 3.648,800 shares of placement and issue of 4.423,87 million subscription shares
Glonghui, May 8 | Columbotai Bio-B (06990.HK) issued an announcement. On May 8, 2024 (before the trading period), the company signed a placement agreement with the placement agent (i.e. Goldman Sachs, Citigroup, J.P. Morgan). According to this, the placement agent already agreed to use individual (but not common or common and individual) as the company's agent to induce the placement of at least six undertakers (and purchase them themselves if the placement is not possible). Shares 150.00 HKD. Placing price Placing per share
Citigroup, Goldman Sachs Among Banks Acting as Placing Agent for Sichuan Kelun-Biotech Biopharmaceutical
Citigroup, Goldman Sachs Among Banks Acting as Placing Agent for Sichuan Kelun-Biotech Biopharmaceutical
Sichuan Kelun-Biotech Biopharmaceutical Placing Shares at 6.8% Discount to Last Traded Price of HK$161.0/share
Sichuan Kelun-Biotech Biopharmaceutical Placing Shares at 6.8% Discount to Last Traded Price of HK$161.0/share
Sichuan Kelun-Biotech Biopharmaceutical Seeks to Raise HK$540.5M in Net Proceeds From Share Placement
Sichuan Kelun-Biotech Biopharmaceutical Seeks to Raise HK$540.5M in Net Proceeds From Share Placement
Kelun-Biotech's Lung Cancer Drug Advances to Phase 2 Trials in US; Shares Up 8%
The US Food and Drug Administration (FDA) has greenlit Sichuan Kelun-Biotech Biopharmaceutical's (HKG:6990) drug A400 to proceed to Phase 2 clinical trials, according to a Friday filing on the Hong Ko
No Data